Meta-analysis of ketamine versus other analgosedatives in critically ill children receiving invasive mechanical ventilation

This systematic review and meta-analysis examined the use of continuous ketamine infusion as an analgosedative in critically ill children receiving invasive mechanical ventilation. The study population comprised 1,436 patients across included trials, comparing ketamine against other analgosedatives. The setting involved pediatric intensive care units where patients required invasive mechanical ventilation. The review aimed to clarify the role of ketamine in this specific demographic, addressing gaps in current sedation strategies for this vulnerable population.

Regarding the primary outcome of mechanical ventilation duration, the meta-analysis found that ketamine may have no effect. The mean difference was reported as 0.00 days, with a 95% confidence interval ranging from 0.03 days fewer to 0.03 days more. The p-value was not reported for this specific comparison, but the direction of effect indicated no significant difference between the groups. This suggests that ketamine does not shorten or prolong the duration of invasive mechanical ventilation in this context.

For opioid exposure, the analysis indicated that ketamine may reduce cumulative fentanyl requirements. The mean difference was -8.88 micrograms per kilogram of cumulative fentanyl equivalents. The 95% confidence interval for this reduction ranged from -6.99 to -10.77 micrograms per kilogram. This finding suggests a potential benefit in opioid-sparing strategies, though the evidence certainty for this outcome was classified as low due to imprecision.

Secondary outcomes including delirium, withdrawal, length of stay, clinically important hypotension, and mortality showed uncertain effects. No specific effect sizes, absolute numbers, p-values, or confidence intervals were reported for these outcomes. The review could not determine whether ketamine influenced the incidence of delirium, the risk of withdrawal symptoms, the total length of hospital stay, the occurrence of clinically important hypotension, or overall mortality rates in this population.

Safety and tolerability data were not reported in the included studies. Adverse events, serious adverse events, discontinuations, and overall tolerability profiles were not detailed in the meta-analysis. Consequently, the safety profile of continuous ketamine infusion in critically ill children remains undefined based on this evidence. Clinicians must rely on existing pharmacological knowledge and individual patient factors when considering this agent.

The authors noted a paucity of studies contributing to this meta-analysis, which limits the statistical power and generalizability of the findings. The certainty of evidence for patient-important outcomes was very low due to imprecision. Additionally, issues related to the serious risk of bias in the included studies further constrain the reliability of the results. These methodological limitations suggest that the current data cannot definitively support or refute the efficacy of ketamine in this setting.

Clinical implications of this review are tempered by the low certainty of the evidence. While ketamine may reduce opioid exposure, the lack of effect on ventilation duration and the uncertainty regarding mortality and safety outcomes necessitate caution. The review concludes that methodologically rigorous randomized controlled trials are needed to better understand the potential role of ketamine analgosedation in the pediatric intensive care unit. Until such trials are conducted, practice decisions should be made with an awareness of the current evidence gaps.

Several critical questions remain unanswered. The optimal dosing protocols for ketamine in this population have not been established by this review. The long-term effects on neurodevelopmental outcomes or the specific subgroups of critically ill children who might benefit most are unknown. Furthermore, the interaction between ketamine and other sedatives in complex clinical scenarios requires further investigation. The absence of data on withdrawal and delirium highlights a significant gap in understanding the neurological impact of these agents in pediatric critical care.

In summary, this meta-analysis provides preliminary data suggesting ketamine may reduce opioid exposure without affecting mechanical ventilation duration in critically ill children. However, the low certainty of evidence and lack of safety data mean that ketamine cannot be recommended as a standard of care based on this review alone. Clinicians should interpret these findings as hypothesis-generating rather than definitive guidance. Future research must address the serious risk of bias in current studies and prioritize patient-important outcomes such as mortality and neurological sequelae.